Abstract
The bactericidal activity against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients was determined in a 10% concentration of normal serum or autologous cystic fibrosis serum. Of the 167 strains tested, 77 (46%) were sensitive (greater than 95% killed) in normal serum. Mucoid strains were more frequently sensitive than nonmucoid strains. Twenty-three sensitive strains tested in ethyleneglycoltetraacetic acid-chelated serum were resistant (less than 10% killed), suggesting only classical pathway activation. Absorption of cystic fibrosis serum with the autologous P. aeruginosa strain resulted in decreased killing by that serum. All sera, including the chelated and absorbed sera, had comparable total hemolytic complement levels. Patients in poor clinical condition (5 out of 12), in contrast to patients in good or moderate condition(1 out of 30), were more likely to have P. aeruginosa strains that were serum resistant in autologous serum but sensitive in normal serum. Sera from these five patients in poor clinical condition were capable of killing heterologous P. aeruginosa strains. These results suggest the presence of a protective or "blocking" activity in serum from some patients in poor clinical conditions. This association of a blocking activity with clinical condition may signal a transition point in the progression of cystic fibrosis lung disease and thus may be another contributory factor in the failure of the cystic fibrosis host to control infection.
Full text
PDF






Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Doershuk C. F., Matthews L. W., Tucker A. S., Spector S. Evaluation of a prophylactic and therapeutic program for patients with cystic fibrosis. Pediatrics. 1965 Nov;36(5):675–688. [PubMed] [Google Scholar]
- Fine D. P., Marney S. R., Jr, Colley D. G., Sergent J. S., Des Prez R. M. C3 shunt activation in human serum chelated with EGTA. J Immunol. 1972 Oct;109(4):807–809. [PubMed] [Google Scholar]
- Forsgren A., Quie P. G. Influence of the alternate complement pathway in opsonization of several bacterial species. Infect Immun. 1974 Aug;10(2):402–404. doi: 10.1128/iai.10.2.402-404.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Guttman R. M., Waisbren B. A. Bacterial blocking activity of specific IgG in chronic Pseudomonas aeruginosa infection. Clin Exp Immunol. 1975 Jan;19(1):121–130. [PMC free article] [PubMed] [Google Scholar]
- Holby N., Olling S. Pseudomonas aeruginosa infection in cystic fibrosis. Bactericidal effect of serum from normal individuals and patients with cystic fibrosis on P. aeruginosa strains from patients with cystic fibrosis or other diseases. Acta Pathol Microbiol Scand C. 1977 Apr;85(2):107–114. [PubMed] [Google Scholar]
- May J. R., Herrick N. C., Thompson D. Bacterial infection in cystic fibrosis. Arch Dis Child. 1972 Dec;47(256):908–913. doi: 10.1136/adc.47.256.908. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Moss R. B., Lewiston N. J. Immune complexes and humoral response to Pseudomonas aeruginosa in cystic fibrosis. Am Rev Respir Dis. 1980 Jan;121(1):23–29. doi: 10.1164/arrd.1980.121.1.23. [DOI] [PubMed] [Google Scholar]
- Palmer D. L., Reed W. P. Delayed hypersensitivity skin testing. I. Response rates in a hospitalized population. J Infect Dis. 1974 Aug;130(2):132–137. doi: 10.1093/infdis/130.2.132. [DOI] [PubMed] [Google Scholar]
- Peterson P. K., Kim Y., Schmeling D., Lindemann M., Verhoef J., Quie P. G. Complement-mediated phagocytosis of Pseudomonas aeruginosa. J Lab Clin Med. 1978 Dec;92(6):883–894. [PubMed] [Google Scholar]
- Reynolds H. Y., Newball H. H. Analysis of proteins and respiratory cells obtained from human lungs by bronchial lavage. J Lab Clin Med. 1974 Oct;84(4):559–573. [PubMed] [Google Scholar]
- Shwachman H., Kulczycki L. L., Khaw K. T. A report on sixty-five patients over 17 years of age. Pediatrics. 1965 Nov;36(5):689–699. [PubMed] [Google Scholar]
- Thomassen M. J., Boxerbaum B., Demko C. A., Kuchenbrod P. J., Dearborn D. G., Wood R. E. Inhibitory effect of cystic fibrosis serum on pseudomonas phagocytosis by rabbit and human alveolar macrophages. Pediatr Res. 1979 Sep;13(9):1085–1088. doi: 10.1203/00006450-197909000-00030. [DOI] [PubMed] [Google Scholar]
- Thomassen M. J., Demko C. A., Boxerbaum B., Stern R. C., Kuchenbrod P. J. Multiple of isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis. J Infect Dis. 1979 Dec;140(6):873–880. doi: 10.1093/infdis/140.6.873. [DOI] [PubMed] [Google Scholar]
- Thomassen M. J., Demko C. A., Wood R. E., Tandler B., Dearborn D. G., Boxerbaum B., Kuchenbrod P. J. Ultrastructure and function of alveolar macrophages from cystic fibrosis patients. Pediatr Res. 1980 May;14(5):715–721. doi: 10.1203/00006450-198005000-00003. [DOI] [PubMed] [Google Scholar]
- Traub W. H., Kleber I. Selective activation of classical and alternative pathways of human complement by "promptly serum-sensitive" and "delayed serum-sensitive" strains of Serratia marcescens. Infect Immun. 1976 May;13(5):1343–1346. doi: 10.1128/iai.13.5.1343-1346.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
- WAHBA A. H., DARRELL J. H. THE IDENTIFICATION OF ATYPICAL STRAINS OF PSEUDOMONAS AERUGINOSA. J Gen Microbiol. 1965 Mar;38:329–342. doi: 10.1099/00221287-38-3-329. [DOI] [PubMed] [Google Scholar]
- Waisbren B. A., Brown I. A factor in the serum of patients with persisting infection that inhibits the bactericidal activity of normal serum against the organism that is causing the infection. J Immunol. 1966 Sep;97(3):431–437. [PubMed] [Google Scholar]
- Wood R. E. Pseudomonas: the compromised host. Hosp Pract. 1976 Aug;11(8):91–100. doi: 10.1080/21548331.1976.11706983. [DOI] [PubMed] [Google Scholar]
- Young L. S., Armstrong D. Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors. J Infect Dis. 1972 Sep;126(3):257–276. doi: 10.1093/infdis/126.3.257. [DOI] [PubMed] [Google Scholar]
- di Sant'Agnese P. A., Davis P. B. Research in cystic fibrosis (third of three parts). N Engl J Med. 1976 Sep 9;295(11):597–602. doi: 10.1056/NEJM197609092951105. [DOI] [PubMed] [Google Scholar]